TREANDA is indicated for the treatment of patients with chronic lymphocytic leukemia
(CLL). Efficacy relative to first-line therapies other than chlorambucil has not
Important Safety Information
- Allergic Reactions: Patients with a known allergic response to bendamustine
should not take TREANDA.
- Serious Side Effects: TREANDA may cause serious side effects, including low
blood cell counts, infections, unexpected responses to TREANDA when placed in your
blood, sudden and severe allergic responses, kidney failure due to fast breakdown
of cancer cells, other cancers, and leaking of TREANDA out of your vein and into
your surrounding skin. Some of these side effects, such as low blood counts, infections,
and severe allergic skin responses (when TREANDA was given with allopurinol and
other medications known to cause severe allergic skin responses), have caused death.
Tell your doctor right away if you have any of these side effects.
- Changes in Therapy: Some serious side effects may require changes in therapy,
such as lowering the amount of TREANDA given, stopping the use of TREANDA, or waiting
longer than expected between doses of TREANDA.
- Pregnancy: Women should avoid becoming pregnant while using TREANDA because
it may cause fetal harm if you take TREANDA while pregnant.
- Most Common Side Effects: The most common non-blood-related side effects
associated with TREANDA (occurring in ≥15% of patients) are fever, nausea, and vomiting.
The most common blood-related side effects associated with TREANDA (frequency ≥15%)
are low red blood cells (oxygen-carrying cells), low platelets (blood-clotting cells),
and decreased number of three different types of white blood cells (infection-fighting